CLN-978

DRUG4 trials

Sponsors

Cullinan Therapeutics Inc.

Conditions

NHLNHL, Relapsed, AdultRheumatoid Arthritis (RASLESLE (Systemic Lupus)Sjogren DiseaseSjogren's SyndromeSjögren

Phase 1

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruitingNCT05879744

Cullinan Therapeutics Inc.NHL, NHL, Relapsed, Adult

Start: 2023-05-31End: 2027-04-30Target: 90Updated: 2024-05-02

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

RecruitingNCT06613360

Cullinan Therapeutics Inc.SLE, SLE (Systemic Lupus)

Start: 2025-01-21End: 2027-12-01Target: 24Updated: 2026-06-05

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

RecruitingNCT06994143

Cullinan Therapeutics Inc.Rheumatoid Arthritis (RA

Start: 2025-05-19End: 2028-12-30Target: 37Updated: 2026-05-15

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

RecruitingNCT07041099

Cullinan Therapeutics Inc.Sjögren, Sjogren Disease, Sjogren's Syndrome

Start: 2025-10-01End: 2029-03-15Target: 36Updated: 2026-08-11

Related Papers

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood2023-11-024 citations

1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19

Regular and Young Investigator Award Abstracts2023-10-31